Welcome to our dedicated page for Preveceutical news (Ticker: PRVCF), a resource for investors and traders seeking the latest updates and insights on Preveceutical stock.
PreveCeutical Medical Inc. (PRVCF) is an innovative health sciences company developing preventive and curative therapies through advanced biotechnology research. This page serves as the definitive source for verified news and official updates about the company's scientific advancements and corporate developments.
Investors and researchers will find timely updates on PRVCF's progress across multiple therapeutic programs, including its nature-identical peptide research, Sol-Gel drug delivery platform, and non-addictive pain management solutions. Our curated news feed ensures stakeholders stay informed about material events including clinical trial milestones, intellectual property filings, and strategic partnership announcements.
The news collection focuses on three key areas: Research Breakthroughs (gene therapy progress, preclinical study results), Operational Updates (regulatory filings, financial disclosures), and Strategic Developments (collaborations, patent grants). Each update is verified against original source materials to ensure accuracy.
Bookmark this page for streamlined access to PRVCF's latest advancements in preventive health sciences. For comprehensive analysis of how these developments may impact long-term research trajectories, consider subscribing to our investment research updates.
PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) has entered into a Marketing Service Agreement with Outside the Box Capital (OTB) effective September 1, 2024. The agreement, running from September 3, 2024, to March 3, 2025, involves OTB providing various marketing and distribution services to enhance PreveCeutical's visibility and investor engagement.
As compensation, PreveCeutical will pay OTB a cash fee of $150,000 and grant 5,000,000 share purchase options at $0.05 per share, valid for 12 months. The services include content planning for PreveCeutical's YouTube channel, establishing a project ambassador, assisting with social media engagement, and promoting company insights across various platforms to attract new clients and interested parties.
On July 9, 2024, PreveCeutical Medical announced the revocation of the management cease trade order (MCTO) issued by the British Columbia Securities Commission on May 2, 2024. The MCTO was lifted after PreveCeutical successfully filed its interim financial statements, management's discussion and analysis, and CEO/CFO certificates for Q1 2024. These documents are now accessible on SEDAR+. The MCTO had been enforced under National Policy 12-203 due to delays in financial filings.
PreveCeutical Medical has filed its audited annual financial statements and related management's discussion for the year ending December 31, 2023. These filings are now available on SEDAR+ and the CSE website. The company is currently under a management cease trade order (MCTO) issued by the British Columbia Securities Commission due to a delay in filing these reports. PreveCeutical missed the May 30, 2024 deadline for its Q1 2024 financial filings as a result. The company aims to complete the Q1 filings by July 5, 2024, after which it expects the MCTO to be revoked. PreveCeutical will continue issuing bi-weekly updates as required.
PreveCeutical Medical announces a series of unsecured, non-convertible, and interest-free loan agreements totaling $297,731.00. The loans, provided by CEO Stephen Van Deventer and former President Kimberly Van Deventer, aim to support working capital. Stephen Van Deventer's involvement qualifies as a 'related party transaction' under MI 61-101, but the company has exempted from requiring minority shareholder approval.
PreveCeutical Medical provides an update on the Management Cease Trade Order (MCTO) issued by the British Columbia Securities Commission (BCSC) due to delayed filing of its audited annual financial statements for the year ended December 31, 2023. The delay was caused by a lack of funds to engage auditors. The Company has since engaged Smythe LLP and expects to file the required documents by June 28, 2024. Until the filings are complete, PreveCeutical will issue bi-weekly default status reports. The MCTO restricts trading by the Company's executives but does not affect the general public's ability to trade its shares on the Canadian Securities Exchange. PreveCeutical is not undergoing insolvency proceedings and has committed to transparent communication with its creditors and the public.
PreveCeutical Medical provides an update on its Management Cease Trade Order (MCTO) issued by the British Columbia Securities Commission (BCSC) due to a delay in filing its audited annual financial statements for 2023. The delay was caused by a lack of funds, but the company has now engaged Smythe LLP and expects to file the statements by June 28, 2024.
The company also completed the first tranche of a non-brokered private placement, raising $115,000 through the sale of 4,600,000 units at $0.025 per unit. The funds will be used for working capital, including audit fees. Until the filings are complete, the company will issue bi-weekly updates. Trading in the company's shares will continue for the general public, but insiders and officers are restricted. The company is not subject to insolvency proceedings.
PreveCeutical Medical has provided an update on the Management Cease Trade Order (MCTO) issued by the British Columbia Securities Commission due to the company's delay in filing its annual financial statements for the year ended December 31, 2023. The delay was caused by a lack of funds to engage auditors. The company has now engaged Smythe LLP and expects to file the required documents by June 28, 2024. During this period, the CEO, CFO, and certain other officers cannot trade in the company's shares. The general public can continue to trade them. PreveCeutical also plans a private placement to raise up to $250,000 for working capital, including audit fees.
PreveCeutical Medical Inc. announces a Management Cease Trade Order due to missing the deadline for filing annual financial statements. The Company applied for a MCTO as a result of a lack of funds preventing completion of the audit on time. PreveCeutical expects to file the Annual Filings by June 28, 2024, and will provide bi-weekly default status reports until then. Additionally, the Company plans a private placement to raise $250,000 for working capital purposes.
FAQ
What is the current stock price of Preveceutical (PRVCF)?
What is the market cap of Preveceutical (PRVCF)?
